UK Precision Oncology Market Size & Outlook, 2024-2030
UK precision oncology market, 2018-2030 (US$M)
Related Markets
UK precision oncology market highlights
- The UK precision oncology market generated a revenue of USD 6,278.8 million in 2024 and is expected to reach USD 11,100.7 million by 2030.
- The UK market is expected to grow at a CAGR of 10% from 2025 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2024.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
Precision oncology market data book summary
| Market revenue in 2024 | USD 6,278.8 million |
| Market revenue in 2030 | USD 11,100.7 million |
| Growth rate | 10% (CAGR from 2025 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Invitae Corp, Qiagen NV, Illumina Inc, Exact Sciences Corp, Rain Oncology, Strata Oncology, Xilis, Variantyx, BioServe, Relay Therapeutics, Acrivon Therapeutics |
Other key industry trends
- In terms of revenue, UK accounted for 5.4% of the global precision oncology market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK precision oncology market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 8,891.1 million by 2030.
Therapeutics was the largest segment with a revenue share of 78.22% in 2024. Horizon Databook has segmented the UK precision oncology market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The UK precision oncology market is projected to grow at a significant CAGR during the forecast period, due to the increasing emphasis on developing advanced antibody-drug conjugates that target specific cancer biomarkers. For instance, GSK's B7-H3-targeted ADC, which received breakthrough therapy designation from the US FDA in August 2024, for relapsed or refractory extensive-stage small-cell lung cancer, highlights the potential of such therapies. This innovation reflects the growing demand for precision treatments that address complex cancer cases, spurring investment and adoption in the UK market to meet evolving healthcare needs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Precision Oncology Market Scope
Precision Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK precision oncology market size, by product, 2018-2030 (US$M)
UK Precision Oncology Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
